Novartis receives EU approval for Kesimpta, the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

Novartis has announced that the European Commission has approved Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features . Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that has shown superior efficacy with a similar safety profile compared with teriflunomide, a first-line treatment in MS. Kesimpta is the first B-cell therapy that can be self-administered once-monthly at home via the Sensoready autoinjector pen and can be a first-choice treatment option for patients with RMS.